Blockchain-based data privacy management with Nudge theory in open banking

Open banking brings both opportunities and challenges to banks all over the world especially in data management. A blockchain as a continuously growing list of records managed by a peer-to-peer network is widely used in various application scenarios; and it is commonly agreed that the blockchain technology can improve the protection of financial data privacy. However, current blockchain technology still poses some challenges in fully meeting the needs of financial data privacy protection. In order to address the existing problems, this paper proposes a new data privacy management framework based on the blockchain technology for the financial sector. The framework consists of three components: (1) a data privacy classification method according to the characteristics of financial data; (2) a new collaborative-filtering-based model; and (3) a data disclosure confirmation scheme for customer strategies based on the Nudge Theory. We implement a prototype and propose a set of algorithms for this framework. The framework is validated through field experiments and laboratory experiments. © 2019 Elsevier B.V

Comparative Study of IFN-Based Versus IFN-Free Regimens and Their Efficacy in Treatment of Chronic Hepatitis C Infections

The hepatitis C viral (HCV) infection is a global health burden, WHO estimates 130–150 million people chronically infected with hepatitis C virus worldwide. Additional 3–4 million people become newly infected annually and more than 350,000 people die each year of HCV-related liver diseases. HCV infection exhibits higher genetic diversity with regional variations in genotypic prevalence resulting big challenges on disease management. Introduction of DAAs revolutionised the new era of all oral therapy in treatment of chronic hepatitis C infection and is the regimens of choice in present days. However, IFN-based combination therapy with sofosbuvir has promising efficacy in genotypes 3, 4, 5 or 6 infections compared to genotypes 1 and 2 infections. So, these regimens could be an option in DAAs regimen failure cases. The poor availability of data on recent DAAs (IFN-free) regimens questioned on regular use and cost effectiveness is the another challenge with DAAs regimens. So phase III trials (sofosbuvir and velpatasvir) of recent DAAs with pangenotypic actions and better tolerability in HCV infected patients are the future advances in treatment of chronic hepatitis C. After all those recent combination therapies with better SVR, the combination of pegylated interferon with ribavirin is the only option available where unavailability of other regimens still exists